MCID: EMB004
MIFTS: 57

Embryonal Carcinoma

Categories: Cancer diseases, Fetal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Embryonal Carcinoma

MalaCards integrated aliases for Embryonal Carcinoma:

Name: Embryonal Carcinoma 12 52 58 15 17 71
Embryonal Neoplasm 12 17 71
Embryonal Cancer 12 15
Primary Extragonadal Embryonal Carcinoma 12
Extragonadal Embryonal Carcinoma 71
Carcinoma, Embryonal 43
Carcinoma Embryonal 54
Cancer, Embryonal 71
Cancer Embryonal 54
Embryo Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3308 DOID:688
SNOMED-CT 67 28047004
MESH via Orphanet 44 D018236
ICD10 via Orphanet 33 C22.7 C71.9
UMLS via Orphanet 72 C0206659
Orphanet 58 ORPHA180226
UMLS 71 C0027654 C0206659 C0751364 more

Summaries for Embryonal Carcinoma

NIH Rare Diseases : 52 Embryonal carcinoma is a type of testicular cancer , which is cancer that starts in the testicles, the male reproductive glands located in the scrotum. It most often develops in young and middle-aged men. It tends to grow rapidly and spread outside the testicle. Embryonal carcinomas are classified as nonseminoma germ cell tumors . Most testicular cancers grow from germ cells , the cells that make sperm. Germ cell tumors are broadly divided into seminomas and nonseminomas because each type has a different prognosis and treatment regimen. Nonseminomas, which are more common, tend to grow more quickly than seminomas. Nonseminoma tumors are often made up of more than one type of cell, and are identified according to the different cell types.

MalaCards based summary : Embryonal Carcinoma, also known as embryonal neoplasm, is related to ovarian embryonal carcinoma and intratubular embryonal carcinoma. An important gene associated with Embryonal Carcinoma is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are ERK Signaling and Developmental Biology. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include ovaries, testes and testis, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An embryonal cancer that is a type of germ cell tumour that is located in the ovaries or located in the testes.

Wikipedia : 74 Embryonal carcinoma is a relatively uncommon type of germ cell tumour that occurs in the ovaries and... more...

Related Diseases for Embryonal Carcinoma

Diseases related to Embryonal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 ovarian embryonal carcinoma 34.6 TNFRSF8 SOX2 POU5F1 AFP
2 intratubular embryonal carcinoma 34.3 TNFRSF8 POU5F1 KIT AFP
3 endodermal sinus tumor 33.4 TNFRSF8 POU5F1 MIR302A KIT AFP
4 teratocarcinoma 33.4 TDGF1 RARB RARA POU5F1 MIR302A FGF4
5 germ cell and embryonal cancer 33.2 TDGF1 SOX2 POU5F1 NES MIR302A KIT
6 teratoma 31.3 SOX2 POU5F1 NES KIT H19 AFP
7 mixed germ cell tumor 31.3 KIT AFP
8 seminoma 31.2 TNFRSF8 SOX2 POU5F1 KIT AFP
9 ovarian germ cell cancer 30.7 POU5F1 KIT AFP
10 mature teratoma 30.6 TNFRSF8 POU5F1 MIR302A KIT AFP
11 malignant teratoma 30.5 TNFRSF8 SOX2 POU5F1 KIT AFP
12 mediastinum seminoma 30.5 KIT AFP
13 central nervous system germinoma 30.4 POU5F1 MIR302A
14 brain germinoma 30.4 POU5F1 KIT ESRG AFP
15 germinoma 30.4 POU5F1 MIR302A KIT ESRG AFP
16 dysgerminoma of ovary 30.3 KIT AFP
17 germ cell cancer 30.1 SOX2 POU5F1 NES MIR302A KIT H19
18 wilms tumor 1 30.0 PODXL KIT H19 AFP
19 neuroblastoma 29.5 SOX2 RARS1 POU5F1 NES KIT HOTAIR
20 medulloblastoma 29.0 SOX2 POU5F1 NES KIT HOTAIR H19
21 childhood ovarian embryonal carcinoma 12.5
22 central nervous system embryonal carcinoma 12.4
23 adult central nervous system embryonal carcinoma 12.3
24 non-central nervous system-localized embryonal carcinoma 12.3
25 embryonal testis carcinoma 12.2
26 testicular germ cell tumor 12.0
27 childhood embryonal testis carcinoma 11.5
28 polyembryoma 11.5
29 childhood teratocarcinoma of the testis 11.2
30 pediatric cns embryonal cell carcinoma 11.2
31 atypical teratoid rhabdoid tumor 11.1
32 hemihyperplasia, isolated 11.1
33 kidney rhabdoid cancer 11.1
34 simpson-golabi-behmel syndrome 11.1
35 extragonadal seminoma 10.7 KIT AFP
36 ovarian mixed germ cell neoplasm 10.7 KIT AFP
37 gallbladder leiomyosarcoma 10.6 KIT AFP
38 mixed germ cell-sex cord neoplasm 10.6 POU5F1 KIT
39 ovarian primitive germ cell tumor 10.6 POU5F1 AFP
40 ovarian endodermal sinus tumor 10.6 POU5F1 AFP
41 liver lymphoma 10.6 FGF4 AFP
42 central nervous system immature teratoma 10.6 SOX2 NES
43 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.6 RARS1 RARB RARA
44 hypervitaminosis a 10.6 RARS1 RARG RARA
45 endometrial small cell carcinoma 10.6 KIT AFP
46 liver leiomyosarcoma 10.6 KIT AFP
47 tyrosinemia 10.5 SOX2 POU5F1 AFP
48 germ cells tumors 10.5
49 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.5 RARS1 KIT
50 ovarian solid teratoma 10.5 TNFRSF8 AFP

Graphical network of the top 20 diseases related to Embryonal Carcinoma:



Diseases related to Embryonal Carcinoma

Symptoms & Phenotypes for Embryonal Carcinoma

GenomeRNAi Phenotypes related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.44 AFP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.44 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.44 POU5F1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.44 POU5F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.44 POU5F1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.44 NDN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.44 AFP NDN POU5F1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.44 AFP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.44 POU5F1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.44 AFP
11 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.44 POU5F1

MGI Mouse Phenotypes related to Embryonal Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 BMP4 FGF4 GDF3 KIT NDN POU5F1
2 embryo MP:0005380 10.07 BMP4 FGF4 GDF3 KIT POU5F1 RARA
3 endocrine/exocrine gland MP:0005379 9.97 AFP BMP4 KIT POU5F1 RARA RARB
4 digestive/alimentary MP:0005381 9.95 BMP4 KIT POU5F1 RARA RARB RARG
5 normal MP:0002873 9.9 BMP4 FGF4 GDF3 KIT NDN POU5F1
6 hearing/vestibular/ear MP:0005377 9.73 BMP4 KIT RARA RARB RARG SOX2
7 reproductive system MP:0005389 9.61 AFP BMP4 FGF4 KIT POU5F1 RARA
8 respiratory system MP:0005388 9.23 BMP4 FGF4 KIT NDN RARA RARB

Drugs & Therapeutics for Embryonal Carcinoma

Drugs for Embryonal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Ribavirin Approved Phase 3 36791-04-5 37542
4
Palivizumab Approved, Investigational Phase 3 188039-54-5
5
Captopril Approved Phase 3 62571-86-2 44093
6
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
7
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
8
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
9
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
10
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
11
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
17
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
18
Vinblastine Approved Phase 3 865-21-4 13342 241903
19 Liver Extracts Phase 3
20 Antiviral Agents Phase 3
21 Anti-Infective Agents Phase 3
22 Hormone Antagonists Phase 3
23 Immunosuppressive Agents Phase 3
24 Hormones Phase 3
25
protease inhibitors Phase 3
26 Antihypertensive Agents Phase 3
27 HIV Protease Inhibitors Phase 3
28 Antirheumatic Agents Phase 3
29 Angiotensin-Converting Enzyme Inhibitors Phase 3
30 Cytochrome P-450 CYP3A Inhibitors Phase 3
31 Cytochrome P-450 Enzyme Inhibitors Phase 3
32
Hydroxyitraconazole Phase 3
33 Antifungal Agents Phase 3
34 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
35 Steroid Synthesis Inhibitors Phase 3
36 Antiparasitic Agents Phase 3
37 Liposomal amphotericin B Phase 3
38 Antiprotozoal Agents Phase 3
39 Anti-Bacterial Agents Phase 3
40 Topoisomerase Inhibitors Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Etoposide phosphate Phase 3
43 Podophyllotoxin Phase 3 518-28-5
44 Alkylating Agents Phase 3
45
Isophosphamide mustard Phase 3 0
46 Antimitotic Agents Phase 3
47 Albumin-Bound Paclitaxel Phase 3
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
50
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
2 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
3 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
4 A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
5 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
6 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
7 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
8 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
9 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
12 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
13 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
14 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
15 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
16 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
17 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
18 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
19 Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
20 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
21 Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
22 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
23 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
24 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
25 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
26 A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION Completed NCT00002673 Phase 2
27 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
28 Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial. Completed NCT01851200 Phase 2 Brentuximab Vedotin
29 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
30 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
31 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
32 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
33 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Recruiting NCT00432094 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel;thiotepa;Mesna
34 Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Recruiting NCT03012620 Phase 2 Pembrolizumab
35 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
36 A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) Active, not recruiting NCT02798406 Phase 2
37 A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Terminated NCT02689219 Phase 2 Brentuximab Vedotin
38 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
39 CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
40 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
41 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride
42 Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed by One Week's Rest Completed NCT00003982 Phase 1 sabarubicin
43 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
44 A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen Completed NCT00004604 Phase 1
45 Phase I Study of CCI-779 (NSC 683864) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumours Completed NCT00408655 Phase 1 paclitaxel;carboplatin;temsirolimus
46 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
47 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
48 A Phase I Study of Infusion of HER-2/Neu Specific T Cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine Completed NCT00228358 Phase 1 ex vivo-expanded HER2-specific T cells;cyclophosphamide
49 A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors Completed NCT00313599 Phase 1 lapatinib;paclitaxel
50 A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors Active, not recruiting NCT00436254 Phase 1

Search NIH Clinical Center for Embryonal Carcinoma

Cochrane evidence based reviews: carcinoma, embryonal

Genetic Tests for Embryonal Carcinoma

Anatomical Context for Embryonal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Embryonal Carcinoma:

19
Ovaries, Testes

MalaCards organs/tissues related to Embryonal Carcinoma:

40
Testis, Ovary, Testes, Brain, Pineal, Lymph Node, Bone

Publications for Embryonal Carcinoma

Articles related to Embryonal Carcinoma:

(show top 50) (show all 4176)
# Title Authors PMID Year
1
Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. 54 61
20185298 2010
2
Expression of embryonic stem cell markers in cultured JKT-1, a cell line derived from a human seminoma. 54 61
19226408 2010
3
Analysis of SOX2 expression in developing human testis and germ cell neoplasia. 54 61
19876845 2010
4
Reprogramming of Xist against the pluripotent state in fusion hybrids. 54 61
19843582 2009
5
Necdin: a multi functional protein with potential tumor suppressor role? 54 61
19626646 2009
6
Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours. 54 61
19912360 2009
7
The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. 54 61
19221495 2009
8
Midkine translocated to nucleoli and involved in carcinogenesis. 54 61
19152444 2009
9
miR-302b maintains "stemness" of human embryonal carcinoma cells by post-transcriptional regulation of Cyclin D2 expression. 54 61
18930031 2008
10
Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell. 54 61
18502188 2008
11
Nestin expression in central nervous system germ cell tumors. 54 61
18092184 2008
12
Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. 54 61
17941089 2008
13
Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. 54 61
18045648 2008
14
Dynamic and selective interactions of the transcriptional corepressor TIF1 beta with the heterochromatin protein HP1 isotypes during cell differentiation. 54 61
17381543 2007
15
Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells. 54 61
17663992 2007
16
Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. 54 61
17880687 2007
17
Testicular maturation arrest to testis cancer: spectrum of expression of the vitamin D receptor and vitamin D treatment in vitro. 54 61
17644135 2007
18
Transcriptional regulation of human Oct4 by steroidogenic factor-1. 54 61
17226773 2007
19
[Malignant ovarian germ cell tumours: a trial of 36 cases]. 54 61
17350873 2007
20
Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. 54 61
17314394 2007
21
Q2ChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells. 54 61
17272500 2007
22
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. 54 61
17234757 2007
23
OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. 54 61
17117392 2007
24
Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. 54 61
17324942 2007
25
Oncofetal protein glypican-3 in testicular germ-cell tumor. 54 61
16896894 2006
26
Differential activity of the FGF-4 enhancer in F9 and P19 embryonal carcinoma cells. 54 61
16523502 2006
27
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. 54 61
16793513 2006
28
OAZ regulates bone morphogenetic protein signaling through Smad6 activation. 54 61
16373339 2006
29
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. 54 61
16424014 2006
30
The crystal structure of CREG, a secreted glycoprotein involved in cellular growth and differentiation. 54 61
16344469 2005
31
CD30 (Ki-1) molecule expression in human embryonal epithelial cells of the basal layer of the developing epidermis and epidermal buds and its potential significance for embryogenesis. 54 61
16200333 2005
32
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. 54 61
15994931 2005
33
Distal enhancer of the mouse FGF-4 gene and its human counterpart exhibit differential activity: critical role of a GT box. 54 61
15803454 2005
34
Targeted inhibition of the transcription factor YY1 in an embryonal carcinoma cell line results in retarded cell growth, elevated levels of p53 but no increase in apoptotic cell death. 54 61
16003908 2005
35
Overexpression of anti-apoptotic Mcl-1 in testicular germ cell tumours. 54 61
15842635 2005
36
OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. 54 61
15725806 2005
37
NF-Y behaves as a bifunctional transcription factor that can stimulate or repress the FGF-4 promoter in an enhancer-dependent manner. 54 61
16128003 2005
38
Human embryonal epithelial cells of the developing small intestinal crypts can express the Hodgkin-cell associated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestation. 54 61
15644135 2005
39
Retinoic acid-induced neural differentiation of P19 embryonal carcinoma cells is potentiated by leukemia inhibitory factor. 54 61
15641927 2005
40
Oncogenic role of NALP7 in testicular seminomas. 54 61
15596043 2004
41
Sox7 plays crucial roles in parietal endoderm differentiation in F9 embryonal carcinoma cells through regulating Gata-4 and Gata-6 expression. 54 61
15542856 2004
42
Transcription factor Sox-2 inhibits co-activator stimulated transcription. 54 61
15349837 2004
43
Necdin interacts with the Msx2 homeodomain protein via MAGE-D1 to promote myogenic differentiation of C2C12 cells. 54 61
15272023 2004
44
Association of the transcriptional corepressor TIF1beta with heterochromatin protein 1 (HP1): an essential role for progression through differentiation. 54 61
15342492 2004
45
Receptor interacting protein 140 as a thyroid hormone-dependent, negative co-regulator for the induction of cellular retinoic acid binding protein I gene. 54 61
15130509 2004
46
Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. 54 61
15342930 2004
47
Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140. 54 61
14506269 2003
48
Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research? 54 61
12832377 2003
49
p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis. 54 61
12777997 2003
50
Islet cell hyperplasia in transgenic mice overexpressing EAT/mcl-1, a bcl-2 related gene. 54 61
12782407 2003

Variations for Embryonal Carcinoma

Cosmic variations for Embryonal Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88315457 KIT ovary,NS,germ cell tumour,embryonal carcinoma c.1965T>A p.N655K 4:54728096-54728096 6
2 COSM133536937 AKT1 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6
3 COSM105585949 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6
4 COSM134536549 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6
5 COSM103843275 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6
6 COSM89234463 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6
7 COSM136350617 ovary,NS,germ cell tumour,embryonal carcinoma c.967G>A p.D323N 14:104773083-104773083 6

Expression for Embryonal Carcinoma

Search GEO for disease gene expression data for Embryonal Carcinoma.

Pathways for Embryonal Carcinoma

Pathways related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 TNFRSF8 TDGF1 SOX2 RARG RARB RARA
2
Show member pathways
13.36 TDGF1 SOX2 RARG RARB RARA POU5F1
3 12.7 RARB RARA KIT FGF4 BMP4
4
Show member pathways
12.27 TDGF1 SOX2 POU5F1 FGF4 BMP4
5
Show member pathways
12.22 SOX2 RARG RARB POU5F1 GDF3 BMP4
6 11.98 TDGF1 SOX2 POU5F1 BMP4 AFP
7
Show member pathways
11.71 RARG RARB RARA
8 11.6 SOX2 NES FGF4 BMP4
9
Show member pathways
11.55 RARG RARB RARA
10 11.49 SOX2 POU5F1 MIR302A
11
Show member pathways
11.39 TDGF1 SOX2 POU5F1
12 11.37 KIT FGF4 BMP4
13 11.31 RARG RARB RARA
14 11.29 RARG RARB RARA
15 11.29 SOX2 POU5F1 PODXL NES FGF4 BMP4
16 11.18 RARG RARB RARA
17 11.18 SOX2 POU5F1 KIT BMP4
18 10.77 SOX2 POU5F1 FGF4
19
Show member pathways
10.13 SOX2 POU5F1 BMP4

GO Terms for Embryonal Carcinoma

Cellular components related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II transcription factor complex GO:0090575 8.8 RARG RARB RARA

Biological processes related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 TNFRSF8 TDGF1 RARB RARA KIT GDF3
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 SOX2 RARG RARB RARA POU5F1 NDN
3 cell differentiation GO:0030154 10.17 TDGF1 SOX2 RARG RARB RARA FGF4
4 negative regulation of transcription by RNA polymerase II GO:0000122 10.16 SOX2 RARG RARB RARA POU5F1 BMP4
5 negative regulation of apoptotic process GO:0043066 10.09 TDGF1 RARB RARA FGF4 BMP4
6 positive regulation of cell proliferation GO:0008284 10.08 TDGF1 RARG RARA KIT FGF4 BMP4
7 positive regulation of gene expression GO:0010628 10.03 RARG RARA POU5F1 KIT FGF4 BMP4
8 negative regulation of cell proliferation GO:0008285 10.02 TNFRSF8 RARG RARB RARA NDN BMP4
9 multicellular organism development GO:0007275 10.02 SOX2 RARG RARB RARA POU5F1 NES
10 positive regulation of cell migration GO:0030335 9.99 TDGF1 PODXL KIT BMP4
11 regulation of gene expression GO:0010468 9.97 SOX2 RARG POU5F1 FGF4 BMP4
12 positive regulation of neuron differentiation GO:0045666 9.87 RARB RARA BMP4
13 multicellular organism growth GO:0035264 9.87 RARG RARB RARA
14 BMP signaling pathway GO:0030509 9.86 TDGF1 GDF3 BMP4
15 neural tube closure GO:0001843 9.86 RARG RARA BMP4
16 cellular response to retinoic acid GO:0071300 9.85 RARG RARB RARA
17 SMAD protein signal transduction GO:0060395 9.84 GDF3 BMP4 AFP
18 hormone-mediated signaling pathway GO:0009755 9.83 RARG RARB RARA
19 response to retinoic acid GO:0032526 9.82 RARG RARB RARA
20 somatic stem cell population maintenance GO:0035019 9.8 TDGF1 SOX2 POU5F1 KIT
21 ureteric bud development GO:0001657 9.79 RARB RARA BMP4
22 bone morphogenesis GO:0060349 9.79 RARG RARB RARA
23 outflow tract septum morphogenesis GO:0003148 9.77 RARB RARA BMP4
24 bone development GO:0060348 9.76 RARG RARB RARA BMP4
25 response to lipid GO:0033993 9.75 RARG RARB RARA
26 steroid hormone mediated signaling pathway GO:0043401 9.73 RARG RARB RARA BMP4
27 negative regulation of chondrocyte differentiation GO:0032331 9.71 RARG RARB BMP4
28 face development GO:0060324 9.7 RARG RARA
29 regulation of myelination GO:0031641 9.7 RARG RARB RARA
30 retinoic acid receptor signaling pathway GO:0048384 9.69 RARG RARB RARA
31 positive regulation of programmed cell death GO:0043068 9.68 RARG RARB
32 embryonic eye morphogenesis GO:0048048 9.67 RARG RARB
33 glomerular visceral epithelial cell development GO:0072015 9.67 PODXL BMP4
34 lymphoid progenitor cell differentiation GO:0002320 9.66 KIT BMP4
35 cranial suture morphogenesis GO:0060363 9.65 FGF4 BMP4
36 embryonic camera-type eye development GO:0031076 9.65 RARG RARA NES
37 chondroblast differentiation GO:0060591 9.64 RARA FGF4
38 ventricular cardiac muscle cell differentiation GO:0055012 9.64 RARB RARA
39 endodermal cell fate specification GO:0001714 9.63 SOX2 POU5F1
40 trachea cartilage development GO:0060534 9.62 RARG RARA
41 regulation of cell fate commitment GO:0010453 9.6 GDF3 BMP4
42 growth plate cartilage development GO:0003417 9.58 RARG RARB RARA
43 negative regulation of cartilage development GO:0061037 9.5 RARG RARB RARA
44 embryonic hindlimb morphogenesis GO:0035116 9.46 RARG RARB FGF4 BMP4
45 gland development GO:0048732 9.43 RARG RARB RARA
46 glandular epithelial cell development GO:0002068 9.13 RARG RARB RARA
47 epithelium development GO:0060429 8.92 RARG RARB RARA BMP4

Molecular functions related to Embryonal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear receptor transcription coactivator activity GO:0030374 9.5 RARG RARB RARA
2 growth factor activity GO:0008083 9.46 TDGF1 GDF3 FGF4 BMP4
3 steroid hormone receptor activity GO:0003707 9.43 RARG RARB RARA
4 retinoid X receptor binding GO:0046965 9.37 RARG RARB
5 nuclear receptor activity GO:0004879 9.13 RARG RARB RARA
6 transcription regulatory region sequence-specific DNA binding GO:0000976 9.02 SOX2 RARG RARB RARA POU5F1

Sources for Embryonal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....